Advanced Search
NING Zhonghua, PEI Honglei, XU Guoping, HAN Yang, XI Dan, HUANG Jin. Impact of PCNA, p53 and Nm23 Expression and Adjuvant Radiotherapy on Prognosis of Advanced Thoracic Esophageal Squamous Cell Carcinoma Patients After Operation[J]. Cancer Research on Prevention and Treatment, 2014, 41(11): 1209-1214. DOI: 10.3971/j.issn.1000-8578.2014.11.011
Citation: NING Zhonghua, PEI Honglei, XU Guoping, HAN Yang, XI Dan, HUANG Jin. Impact of PCNA, p53 and Nm23 Expression and Adjuvant Radiotherapy on Prognosis of Advanced Thoracic Esophageal Squamous Cell Carcinoma Patients After Operation[J]. Cancer Research on Prevention and Treatment, 2014, 41(11): 1209-1214. DOI: 10.3971/j.issn.1000-8578.2014.11.011

Impact of PCNA, p53 and Nm23 Expression and Adjuvant Radiotherapy on Prognosis of Advanced Thoracic Esophageal Squamous Cell Carcinoma Patients After Operation

More Information
  • Received Date: September 03, 2013
  • Revised Date: January 14, 2014
  • Objective To investigate the impact of PCNA, p53 and Nm23 expression and adjuvant radiotherapy on the prognosis of locally advanced thoracic esophageal squamous cell carcinoma patients after operation. Methods From March 2005 to December 2009, 222 patients with locally advanced thoracic esophageal carcinoma received radical esophagectomy in the Third Affiliated Hospital of Soochow University. We analyzed the correlation between the expression of PCNA, p53, Nm23 and clinicopathological factors as well as recurrence, metastasis. Kaplan-Meier method was used to calculate the survival rates. Log-rank and Cox proportional model were used to analyze the impact of PCNA, p53 and Nm23 expression and adjuvant radiotherapy on the prognosis of locally advanced thoracic esophageal squamous cell carcinoma patients after operation. Results The expression of PCNA and p53 were closely correlated with tumor differentiation. The expression of Nm23 had no obvious correlation with clinicopathological factors. PCNA and p53 expression, tumor stage and adjuvant radiotherapy were the significant factors for local recurrence or distant metastasis after operation. Univariate and multivariate analysis showed that PCNA and p53 expression, tumor differentiation, TMN stage and adjuvant radiotherapy were the independent prognostic factors for the OS of the patients after radical esophagectomy. Conclusion PCNA and p53 expression, not Nm23, are the key biologic predictive factors for the survival of locally advanced thoracic esophageal carcinoma patients after operation. Advanced thoracic esophageal squamous cell carcinoma patients with the negative expression of PCNA and p53 will benefit more from postoperative adjuvant radiotherapy.
  • [1]
    Almhanna K, Strosberg JR. Multimodality approach for locally advanced esophageal cancer[J]. World J Gastroenterol, 2012, 18 (40) : 5679-87.
    [2]
    Xiao ZF, Yang ZY, Liang J, et al. Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients[J]. Ann Thorac Surg, 2003, 75 (2): 331-6.
    [3]
    Xiao ZF, Yang ZY, Miao YJ, et al. Influence of number of metastatic lymph nodes on survival of curative resected thoracic esophageal cancer patients and value of radiotherapy: report of 54 9 cases[J]. Int J Radiat Oncol Biol Phys, 2005, 62 (1): 82-90.
    [4]
    Li Q, Wu SG, Gao JM, et al. Impact of esophageal cancer staging on overall survival and disease-free survival based on the 2010 AJCC classification by lymph nodes[J]. J Radiat Res, 2013, 54 (2): 30 7-14.
    [5]
    Malthaner RA, Wong RK, Rumble RB, et al. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis[J]. BMC Med, 2004, 2: 35.
    [6]
    Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction[J]. Ann Surg Oncol, 2010, 17 (7): 1721-4.
    [7]
    Strzalka W, Ziemienowicz A. Proliferating cell nuclear antigen (PCNA): a key factor in DNA replication and cell cycle regulation[J]. Ann Bot, 2011, 107 (7): 1127-40.
    [8]
    Kimos MC, Wang S, Borkowski A, et al. Esophagin and proliferating cell nuclear antigen (PCNA) are biomarkers of human esophageal neoplastic progression[J]. Int J Cancer, 2004, 11 1 (3): 415-7.
    [9]
    Kii T, Takiuchi H, Kawabe S, et al. Evaluation of prognostic factors of esophageal squamous cell carcinoma (stage II-III) after concurrent chemoradiotherapy using biopsy specimens[J]. Jpn J Clin Oncol, 2007, 37 (8): 583-9.
    [10]
    Sugahara S, Ohara K, Takahashi A, et al. Prognostic significance of the PC10 index for patients with stage II and III oesophageal cancer treated with radiotherapy[J]. Acta Oncol, 1999, 38 (8): 10 57-62.
    [11]
    Muller PA, Vousden KH. p53 mutations in cancer[J]. Nat Cell Biol, 2013, 15 (1): 2-8.
    [12]
    Lam KY, Loke SL, Chen WZ, et al. Expression of p53 in oesophageal squamous cell carcinoma in Hong Kong Chinese[J]. Eur J Surg Oncol, 1995, 21(3): 242-7.
    [13]
    Tachibana M, Yoshimura H, Kinugasa S, et al. Postoperative chemotherapy vs. chemoradiotherapy for thoracic esophageal cancer: a prospective randomized clinical trial[J]. Eur J Surg Oncol, 2003, 29 (7): 580-7.
    [14]
    Shimoji H, Miyazato H, Nakachi A, et al. Expression of p53, bcl-2, and bax as predictors of response to radiotherapy in esophageal cancer[J]. Dis Esophagus, 2000, 13 (3): 185-90.
    [15]
    Yamamoto Y, Yamai H, Seike J, et al. Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin[J]. Ann Surg Oncol, 2012, 19 (3): 757-65.
    [16]
    Boissan M, Dabernat S, Peuchant E, et al. The mammalian Nm23/ NDPK family: from metastasis control to cilia movement[J]. Mol Cell Biochem, 2009, 329 (1-2): 51-62.
    [17]
    Liu J, Wang YK, Liu Y, et al. The effect of postoperative chemotherapy after esophagectomy on the survival rate to patients with original squamous cell carcinoma of esophagus[J]. Zhonghua Liu Xing Bing Xue Za Zhi, 2004, 25 (4): 346-50. [刘静, 王永康, 刘莹, 等.术后辅助化疗对食管鳞状细胞癌患者生存率的影响 [J] 中华流行病学杂志, 2004, 25 (4): 346-50.]
    [18]
    Szumilo J, Skomra D, Chibowski D, et al. Immunoexpression of nm23 in advanced esophageal squamous cell carcinoma[J]. Folia Histochem Cytobiol, 2002, 40 (4): 377-80.
    [19]
    Sarris M, Konopka M, Lee CS. Differential expression of the nm23 protein in the progression of oesophageal adenocarcinoma[J]. Pathology, 2003, 35 (1): 37-41.
  • Related Articles

    [1]ZHAO Hongyu, ZENG Liang. Advances in Immunohistochemical Markers in Molecular Classification of Medulloblastoma[J]. Cancer Research on Prevention and Treatment, 2018, 45(4): 247-252. DOI: 10.3971/j.issn.1000-8578.2018.17.1186
    [2]YANG Zhenhua, YE Liang, FANG Surong, GU Wei. Clinical Significance of Immunohistochemistry in Detecting Epidermal Growth Factor Receptor Mutation in Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2016, 43(4): 272-276. DOI: 10.3971/j.issn.1000-8578.2016.04.007
    [3]ZHOU Linyan, WAN Meizhen, LIU Yongping, CHEN Yufang. Assessment of Microsatallite Instability in Colorectal Carcinoma: A Comparison Between Immunohistochemistry and PCR Method[J]. Cancer Research on Prevention and Treatment, 2015, 42(12): 1231-1234. DOI: 10.3971/j.issn.1000-8578.2015.12.013
    [4]ZHANG Meng, PENG Li, QIAO Zhi-bin, HE Hong-tao, ZHOU Ye, XU Zhuo, YANG Tao, LIANG Zhan-qiang. Expression and Clinical Significance of pAkt, Skp2 and P27kip1 Protein in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2011, 38(11): 1283-1287. DOI: 10.3971/j.issn.1000-8578.2011.11.017
    [5]LIU Hua-qing, HU-Li. Application of Combination of Double-labelling with Immunohistochemistry and Laser Capture Microdissection in Hodgkin's Lymphoma[J]. Cancer Research on Prevention and Treatment, 2010, 37(04): 438-440. DOI: 10.3971/j.issn.1000-8578.2010.04.019
    [6]CHEN Chun-mei, XIA He-shun, WU Jian-Ping, . A Study on Fiberbronchoscope,Clinicopathology and Immunohistochemistry of Lung Small Cell Carcinoma[J]. Cancer Research on Prevention and Treatment, 1999, 26(5): 344-346.
    [7]Peng Shanyou, Li Hui, Xiong Guosheng, . Pathological and Immunohistochemistrical Study in 57 Cases of Uterine Cervix Adenocarcinoma[J]. Cancer Research on Prevention and Treatment, 1999, 26(2): 116-117.
    [8]Liu Yunchu, . Immunohistochemical Study of Transforming Growth Factor-β2 in Prostatic Cancer[J]. Cancer Research on Prevention and Treatment, 1998, 25(4): 276-278.
    [9]Xiong Yongyan, . Observations on Histology and Immunohistochemistry in NasopharyngealVesicular Nucleus Cell Carcinoma and Undifferentiated Carcinoma[J]. Cancer Research on Prevention and Treatment, 1996, 23(2): 81-82.
    [10]J. F. Wang, . Immunohistochemical Study of Colonic Carcinoma[J]. Cancer Research on Prevention and Treatment, 1995, 22(6): 347-349.

Catalog

    Article views (1225) PDF downloads (289) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return